Search
for

    Did you mean RU58841?
    GlossaryRU58841

    non-steroidal anti-androgen researched for treating androgenic alopecia

    RU58841 is a non-steroidal anti-androgen that is often researched for its potential to treat androgenic alopecia (pattern hair loss). It works by binding to androgen receptors in the scalp, thereby preventing dihydrotestosterone (DHT) from attaching to these receptors and causing hair follicle miniaturization.

    Related Terms

    Learn

    2 / 2 results

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen

    Research

    5 / 43 results

    Community Join

    5 / 1000+ results

      community To anyone that is still not seeing results on the big 3…

      in Treatment  103 upvotes 2 years ago
      User redh0t12 suggests using a derma pen for hair regrowth, as it helped them after using finasteride and minoxidil. Others discuss their experiences with various treatments, including derma rolling, oral and topical minoxidil, and finasteride, with mixed results.

      community Longterm ru58841 users + my experience

      in Treatment  7 upvotes 1 week ago
      RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.

      community The story of RU58841/PSK3841

      in Research/Science 1 month ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 1 month ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.